Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons (HAART-IPT)

This study has been completed.
Sponsor:
Collaborators:
Medecins Sans Frontieres
Imperial College London
Johns Hopkins University
London School of Hygiene and Tropical Medicine
Information provided by (Responsible Party):
Prof Gary Maartens, University of Cape Town
ClinicalTrials.gov Identifier:
NCT00463086
First received: April 19, 2007
Last updated: July 16, 2012
Last verified: July 2012

April 19, 2007
July 16, 2012
November 2007
November 2011   (final data collection date for primary outcome measure)
Rate of development of TB (microbiologically confirmed TB or highly probable TB) during the 36 month risk period [ Time Frame: Patients are assessed for TB one two monthly at each ART re-fill appointment ] [ Designated as safety issue: Yes ]
Rate of microbiologically confirmed TB or highly probable TB during the 36 month risk period
Complete list of historical versions of study NCT00463086 on ClinicalTrials.gov Archive Site
  • Rate of drug toxicity (specifically, peripheral neuropathy, hepatitis +/-raised ALT grade III or worse and allergic rashes grade III or worse [ Time Frame: during the intervention period (ALT determined at baseline, 1, 2 and 3 months and then 3-monthly. the last safety determination is at 12 months post initiation of the study drug) ] [ Designated as safety issue: Yes ]
  • Proportions adhering to study drug and HAART at the end of each study year as measured by pharmacy refills [ Time Frame: 1 month to two monthly, depending on the individual patient's clinic appointment ] [ Designated as safety issue: Yes ]
  • Rate of development of INH monoresistance during the 36 month risk period. [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
  • Death [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]
  • Worsening ART outcomes (virological and immunological failure) [ Time Frame: CD4+count and viral load are assessed as per clinic protocol (6 monthly post ART initiation) ] [ Designated as safety issue: Yes ]
  • Rate of drug toxicity during and the end of the 36 month risk period
  • Proportions adhering to study drug and HAART at the end of each study year
  • Mortality rate during and at the end of the 36 month risk period
  • Rate of development of INH monoresistance during and at the end of the 36 month risk period.
Not Provided
Not Provided
 
Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons
A Randomized-controlled Trial of Isoniazid Plus Highly Active Antiretroviral Therapy Against Placebo to Prevent Tuberculosis in HIV-infected Persons

The purpose of this study is to evaluate whether isoniazid can safely (and further) reduce the risk of tuberculosis in HIV infected people receiving HAART.

The incidence of Tuberculosis (TB) in poor settlements around Cape Town continues to rise despite highly-active-anti-retroviral therapy (HAART) roll-out and DOTS. In Khayelitsha district, where this project will be conducted, TB incidence is about 1600/100000. There is an equally high HIV prevalence, currently 33%. Over 50% of adults presenting with active TB are co-infected with HIV and a third of all patients starting HAART have active TB. Although HAART has been shown to reduce the overall risk of TB by 59-80%, this risk still far exceeds the general risk. In the Khayelitsha HAART cohort, the risk of developing TB whilst on HAART is ~12 per 100 p-y. In the nearby community of Gugulethu, there is a 14% risk of active TB with at least half of the cases occurring within the first 3months on HAART. In a region where RD1-detected prevalence of latent TB infection is at least 80%, there is a real concern that TB will likely undo the benefit of HAART in the long run. Additional measures are therefore required to reduce the risk of TB in those already receiving or starting HAART. Isoniazid preventive therapy (IPT) represents an option but there is insufficient evidence to determine whether IPT can further (and safely) reduce the risk of TB in the HAART era. In a RCT, we propose to evaluate whether IPT can reduce the risk of active TB in patients receiving HAART.

A total minimum sample size of 1204 is required for the study to detect a 35% reduction in the hazard rates for tuberculosis in the intervention group (h1= 0.052) compared to the control group (h0=0.085) at a power of 80% and a Type II error of 0.05. Our maximum targeted sample size when losses to follow-up and subgroup analyses are considered is 1445. Development of TB will be the primary endpoint.

Additional information (on 10 August 2010):

Recruitment and enrolment into the study was completed in October 2009. We have screened over 2000 patients already on ART and those newly starting ART. However, instead of enrolling our desired maximum sample size of 1445, a revised minimum total of 1368 were instead randomized to the study drug. This followed an amendment to the sample size necessitated by new information on the clinical site; primarily higher rates of patients lost to follow-up at the clinical site than previously anticipated. The amendment to our sample size was reported to, and acknowledged by, the Research Ethics Committee of the University of Cape Town. Follow-up of participants will continue until Oct/November 2011.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Tuberculosis
  • Latent Tuberculosis Infection
  • HIV Infections
  • Drug: isoniazid
    A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
  • Drug: Placebo
    A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
  • Experimental: 1.Isoniazid (INH)
    A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
    Intervention: Drug: isoniazid
  • Placebo Comparator: 2. Placebo
    A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1368
November 2011
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male and female attendees (age ≥18yo) of the Ubuntu HIV and ARV Clinic identified as eligible for the ARV programme will be invited to participate.
  2. Willingness to participate
  3. Able to engage in informed consent procedures

Exclusion Criteria:

  1. Evidence of active TB or suspicion of active TB as determined by a symptoms screening algorithm.
  2. Current TB chemotherapy ( TB treatment completed in the preceding 30 days will not be an exclusion)
  3. Current or previous treatment of latent TB infection since HIV infection (any duration)
  4. Current treatment with fluoroquinolones or other antibiotics with significant anti-tuberculous activity currently being used to treat TB in South Africa
  5. Past reaction/intolerance to INH.
  6. Acute hepatitis or existing Grade III-IV peripheral neuropathy.
  7. Pregnancy or < 6weeks post-partum period (Due to increased risk of hepatotoxicity).
  8. Grade III or higher baseline abnormal liver function. (Note: toxicity grades are all according to ACTG toxicity tables for persons on ART).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
South Africa
 
NCT00463086
HAARTIPT07
Yes
Prof Gary Maartens, University of Cape Town
University of Cape Town
  • Medecins Sans Frontieres
  • Imperial College London
  • Johns Hopkins University
  • London School of Hygiene and Tropical Medicine
Principal Investigator: Gary Maartens (overall PI), FCP University of Cape Town
Study Director: Eric Goemaere (co-investigator), MBBS Medecins Sans Frontieres
Study Director: Molebogeng X Rangaka (Lead Investigator), MBChB University of Cape Town
Study Director: Gilles van Cutsem co-investigator), MBBS Medecins Sans Frontieres
Study Director: Andrew Boulle co-investigator), FCP University of Cape Town
Study Director: Robert J Wilkinson (PI:Immunology Studies), FRCP Wellcome Trust
Study Director: Shahied Mathee (Ubuntu PMO), MBChB Provincial Government of Western Cape
University of Cape Town
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP